Advertisement

Topics

FDA approves Ironwood’s Duzallo for hyperuricemia related to gout

10:30 EDT 22 Aug 2017 | CentreWatch

Ironwood Pharmaceuticals announced Duzallo was approved by the FDA as a once-daily oral treatment for hyperuricemia associated with gout in patients who have not achieved target serum uric acid (sUA) levels with a medically appropriate daily dose of allopurinol alone. Duzallo is not recommended for the treatment of asymptomatic hyperuricemia. Ironwood expects Duzallo to be […]

The post FDA approves Ironwood’s Duzallo for hyperuricemia related to gout appeared first on CenterWatch News Online.

Original Article: FDA approves Ironwood’s Duzallo for hyperuricemia related to gout

NEXT ARTICLE

More From BioPortfolio on "FDA approves Ironwood’s Duzallo for hyperuricemia related to gout"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Gout
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...